Jointown Pharmaceutical Group Co., Ltd (SHA:600998)
China flag China · Delayed Price · Currency is CNY
4.680
-0.060 (-1.27%)
May 28, 2026, 3:00 PM CST

SHA:600998 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
164,017161,251151,695149,981140,282122,359
Other Revenue
138.99138.99115.13158.54142.1648.09
164,156161,390151,810150,140140,424122,407
Revenue Growth (YoY)
7.04%6.31%1.11%6.92%14.72%10.42%
Cost of Revenue
151,512149,008140,075138,140129,560112,636
Gross Profit
12,64512,38211,73512,00010,8649,772
Selling, General & Admin
8,2718,0787,2297,1936,6376,097
Research & Development
116.96128.84146.7196.61178.39194.94
Other Operating Expenses
390.85416.82413.07425.6598.16293.01
Operating Expenses
9,2529,0467,8127,9477,0746,684
Operating Income
3,3933,3363,9234,0533,7903,087
Interest Expense
-1,083-1,014-1,284-1,318-1,221-1,145
Interest & Investment Income
303.191,1411,456255.17490.63310.74
Currency Exchange Gain (Loss)
-11.22-11.22-0.81-4.34-17.05-6.65
Other Non Operating Income (Expenses)
-79.57-83.05-178.79-265.43-281.66-151.72
EBT Excluding Unusual Items
2,5223,3693,9152,7212,7602,094
Impairment of Goodwill
---10.85-1.18--
Gain (Loss) on Sale of Investments
150.3636.79-98.35-78.41.441,235
Gain (Loss) on Sale of Assets
-14.07-251.08-425.835.1145.676.72
Asset Writedown
-16.48-----2.35
Other Unusual Items
135.25135.25257.61344.6230.929.12
Pretax Income
2,7773,2903,6372,9912,8383,363
Income Tax Expense
786.01880.23851.03701.2552.55754.88
Earnings From Continuing Operations
1,9912,4102,7862,2902,2862,608
Minority Interest in Earnings
27.28-154.72-279.05-115.62-200.57-160.05
Net Income
2,0182,2552,5072,1742,0852,448
Net Income to Common
2,0182,2552,5072,1742,0852,448
Net Income Growth
-31.34%-10.07%15.33%4.27%-14.84%-20.38%
Shares Outstanding (Basic)
5,1585,1255,0155,0565,2745,187
Shares Outstanding (Diluted)
5,1585,1255,0155,0565,2745,187
Shares Change (YoY)
1.75%2.19%-0.81%-4.14%1.68%-2.84%
EPS (Basic)
0.390.440.500.430.400.47
EPS (Diluted)
0.390.440.500.430.400.47
EPS Growth
-32.53%-12.00%16.28%8.78%-16.25%-18.06%
Free Cash Flow
2,4322,0392,1073,6992,7432,073
Free Cash Flow Per Share
0.470.400.420.730.520.40
Dividend Per Share
0.2000.2000.2000.1940.1860.112
Dividend Growth
--3.20%4.31%66.64%-39.99%
Gross Margin
7.70%7.67%7.73%7.99%7.74%7.98%
Operating Margin
2.07%2.07%2.58%2.70%2.70%2.52%
Profit Margin
1.23%1.40%1.65%1.45%1.49%2.00%
Free Cash Flow Margin
1.48%1.26%1.39%2.46%1.95%1.69%
EBITDA
3,9653,9424,6654,7304,4163,634
EBITDA Margin
2.42%2.44%3.07%3.15%3.15%2.97%
D&A For EBITDA
571.88605.98742.35676.96626.41547.21
EBIT
3,3933,3363,9234,0533,7903,087
EBIT Margin
2.07%2.07%2.58%2.70%2.70%2.52%
Effective Tax Rate
28.31%26.76%23.40%23.45%19.47%22.45%
Revenue as Reported
164,156161,390151,810150,140140,424122,407
Source: S&P Global Market Intelligence. Standard template. Financial Sources.